Abstract: The invention provides methods, kits, and related compositions for rapid, low-cost, point of care detection of an organism, such as a virus or bacteria, in a biological or environmental sample using isothermal nucleic acid amplification.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: The present disclosure provides NMR relaxation methods for characterizing iron carbohydrate drug products. The methods measure 13C and 1H nuclei relaxation parameters such as T1 and PWHH include performing 2D T1 NMR, 1D 13C NMR and 1H NMR to characterize certain physiochemical properties of iron sucrose drug products, for purposes of assessing bioequivalence between a tested iron sucrose product and a comparator product. The disclosure further provides a novel Fe(III)/Fe(II) reduction method using a new reducing agent Na2S2O5 and an 1H NMR method to monitor the Fe(III)/Fe(II) reduction process.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: An optical element retainer includes a ring body defined about a central axis. The ring body includes an inner diametric surface, an outer diametric surface opposed to the inner diametric surface, a first annular axial surface, and a plurality of flexures extending from a second annular axial surface opposite the first annular axial surface.

Abstract: An optical element retainer includes a ring body defined about a central axis. The ring body includes an inner diametric surface, an outer diametric surface opposed to the inner diametric surface, a first annular axial surface, and a plurality of flexures extending from a second annular axial surface opposite the first annular axial surface.

Abstract: An electronic device including a display configured to display at least one graphical user interface (GUI) element, and a controller configured to identify a user-preferred region preferred by a user on the display and control the display to display the at least one GUI element in the identified user-preferred region.

Abstract: An electronic device including a display configured to display at least one graphical user interface (GUI) element, and a controller configured to identify a user-preferred region preferred by a user on the display and control the display to display the at least one GUI element in the identified user-preferred region.